联合集团(00373)公布，预期2025年上半年公司股东应占综合溢利约16亿港元至18亿港元，而2024年同 期公司股东应占综合亏损则约为2亿港元。财务表现显著改善的原因主要由于(i)天安位于中国上海住宅 项目天安1号二期(C区)单位于2025年初交付予其客户后所确认的溢利上升所致;及(ii)新鸿基主要由于投 资管理业务所带来的投资收益增加以致其应占溢利上升，唯部分被其信贷业务溢利减少所抵销。 ...

智通财经APP讯，联合集团(00373)公布，预期2025年上半年公司股东应占综合溢利约16亿港元至18亿港 元，而2024年同期公司股东应占综合亏损则约为2亿港元。财务表现显著改善的原因主要由于(i)天安位 于中国上海住宅项目天安 1 号二期(C 区)单位于2025年初交付予其客户后所确认的溢利上升所致;及 (ii) 新鸿基主要由于投资管理业务所带来的投资收益增加以致其应占溢利上升，唯部分被其信贷业务溢利减 少所抵销。 ...

Core Insights - The company reported a total revenue of HKD 1.803 billion for the first half of 2025, a decrease of 3.96% year-on-year [1] - Total income increased to HKD 2.8 billion, reflecting a growth of 43.47% year-on-year [1] - Shareholders' profit attributable to the company reached HKD 0.887 billion, a significant increase of 1076% year-on-year [2] - Basic earnings per share were HKD 0.453, with an interim dividend proposed at HKD 0.12 per share [1] Financial Performance - The strong recovery in shareholders' profit was primarily driven by the investment management business, which benefited from an increase in project exits and improved market sentiment towards Chinese-related assets [2] - The investment management segment recorded a pre-tax profit of HKD 0.786 billion, compared to a loss of HKD 0.1475 billion in the same period of 2024 [2] - Performance improvements were noted across nearly all asset classes, including private equity, corporate holdings, hedge funds, special opportunity investments, and structured credit [2] Market Environment - Despite global market challenges due to tariff fluctuations and geopolitical tensions, the investment team achieved strong risk-adjusted returns [1] - The AI breakthroughs from DeepSeek in Hong Kong have rekindled global investor confidence, leading to a resurgence of capital inflow [1] - The Greater China region continues to face economic growth challenges due to weak domestic demand and ongoing structural reforms [1] Strategic Focus - The company emphasizes maintaining a robust balance sheet and ample liquidity as key priorities to capitalize on investment opportunities during market volatility [1] - Following a strategic transformation, the diversified complementary platform is increasingly generating synergies, driving recurring income growth and enhancing long-term shareholder value [1]

格隆汇8月20日丨新鸿基公司(00086.HK)公告，集团于2025年上半年的总收益为2,799.9百万港元（2024 年上半年：1,951.5百万港元）。公司股东应占溢利为887.0百万港元，同比增加10倍以上（2024年上半 年：75.4百万港元）。此强劲复苏主要由投资管理业务所带动，得益于项目的退出增加以及市场对中国 相关资产的情绪转趋乐观，该业务实现可观收益。每股基本盈利为45.3港仙（2024年上半年：3.9港 仙）。董事会宣布派发截至2025年6月30日止六个月的中期股息每股12港仙，与2024年上半年维持不 变。 ...

Core Viewpoint - The company reported a strong recovery in its financial performance for the mid-2025 period, driven by its investment management business, despite facing challenges from global market conditions and geopolitical tensions [1][2]. Financial Performance - Total revenue for the company was HKD 1.803 billion, a decrease of 3.96% year-on-year [1]. - Total income increased to HKD 2.8 billion, reflecting a significant rise of 43.47% year-on-year [1]. - Shareholders' profit attributable to the company was HKD 0.887 billion, showing an impressive increase of over 1076% compared to HKD 0.0754 billion in the first half of 2024 [2]. - Basic earnings per share were HKD 0.453, with a proposed interim dividend of HKD 0.12 per share [1]. Investment Management Business - The investment management segment recorded a pre-tax profit of HKD 0.786 billion, a turnaround from a loss of HKD 0.1475 billion in the same period of 2024 [2]. - The strong performance in this segment was attributed to an increase in project exits and improved market sentiment towards Chinese-related assets [2]. - Almost all asset classes, including private equity, corporate holdings, hedge funds, and special opportunity investments, showed improved performance [2]. Market Conditions and Strategic Focus - The company acknowledged the impact of weak domestic demand and ongoing structural reforms in the Greater China region on economic growth [1]. - Despite these challenges, the company maintained a robust balance sheet and ample liquidity, prioritizing investment opportunities during market volatility [1]. - The completion of the strategic transformation has led to a diversified and complementary platform, enhancing recurring revenue growth and long-term shareholder value [1].

Group 1 - International precious metals market experienced a decline, with silver dropping nearly 2% [1] - As of the close on August 19, 2025 December gold futures fell by $19.1, settling at $3358.9 per ounce, a decrease of 0.57% [1] - The market is cautious ahead of Federal Reserve Chairman Jerome Powell's upcoming speech, leading to a short-term adjustment in precious metal positions [1][2] Group 2 - The US dollar index rose by 0.1%, closing at 98.265, which negatively impacted the precious metals market [2] - The annual Jackson Hole global central bank conference is approaching, with market participants keenly awaiting Powell's policy signals [2] - UBS raised its gold price target for March 2026 by $100 to $3600 per ounce, citing ongoing macroeconomic risks in the US and strong investment demand [2] Group 3 - September silver futures closed down by $0.735, settling at $37.330 per ounce, a decline of 1.93% [3] - December silver futures also fell by $0.74, closing at $37.820 per ounce, a decrease of 1.92% [3]

一、基本情况概述 五届董事会第三十六次会议审议通过了《关于参与投资设立投资基金的议案》， 同意公司出资 5,000 万元与苏州龙瑞创业投资管理有限公司、苏州豪创投资管理 有限公司合作设立苏州龙遨泛人工智能高科技投资中心（有限合伙）（以下简称 "龙遨基金"），具体内容详见公司披露于巨潮资讯网上的《关于参与投资设立 投资基金的公告》（公告编号：2018-044）。 证券代码：002467 证券简称：二六三 公告编号：2025-023 二六三网络通信股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特此公告。 州龙遨泛人工智能高科技投资中心（有限合伙）的议案》，同意公司向龙遨基金 增资 1 亿元人民币，增资后，龙遨基金的注册资本为 5 亿元人民币，公司持有龙 遨基金 30%股权，具体内容详见公司披露于巨潮资讯网上的《关于增资苏州龙遨 泛人工智能高科技投资中心（有限合伙）的公告》（公告编号：2018-091）。 州龙遨泛人工智能高科技投资中心（有限合伙）的议案》，同意公司与苏州龙瑞 创业投资管理有限公司、苏州豪创投资管理有限公司、苏州工业园区元禾秉胜股 权 ...

Company Overview - 华人锦扬（深圳）投资有限公司 has been established with a registered capital of 10 million RMB [1] - The legal representative of the company is 王亚克 [1] - The company is classified under the rental and business services industry, specifically in comprehensive management services [1] Shareholding Structure - 上海瑞夙投资管理有限公司 holds a 70% stake in 华人锦扬 [1] - 上海泽喜瑞科技有限公司 owns a 30% stake in the company [1] Business Scope - The company’s business activities include financing consulting services, enterprise management, enterprise management consulting, venture capital (limited to investments in unlisted companies), social economic consulting services, domestic trade agency, investment activities with self-owned funds, offshore trade operations, trade brokerage, sales agency, information technology consulting services, and information consulting services (excluding licensed information consulting services) [1] - There are no licensed business projects listed for the company [1] Registration Details - The company is registered in Shenzhen, specifically at 深南中路3018号世纪汇18层 [1] - The business license allows for operations until August 18, 2025, with no fixed term thereafter [1]

Group 1 - The core idea of the article is that Jin Chun Co., Ltd. plans to establish a partnership with Shanghai Hongfu Asset Management Co., Ltd. and other limited partners to enhance capital efficiency and resource allocation [1] - The partnership, named "He De Venture Capital Partnership," will have a total scale of RMB 536.8 million, with Jin Chun contributing RMB 10 million of its own funds [1] - Hongfu Asset will act as the general partner and fund manager for the partnership, which will specifically invest in Aifei (Shanghai) Biopharmaceutical Technology Co., Ltd. [1]

Group 1 - The company, Jin Chun Co., Ltd. (300877.SZ), announced plans to establish a partnership with Shanghai Hongfu Asset Management Co., Ltd. and other limited partners to enhance capital efficiency and resource allocation [1] - The partnership, named Shengzhou Hede Venture Capital Partnership (Limited Partnership), will have a total scale of RMB 536.8 million, with the company contributing RMB 10 million from its own funds [1] - Hongfu Asset will act as the general partner and fund manager for the partnership, which will specifically invest in Aifei (Shanghai) Biopharmaceutical Technology Co., Ltd. [1]